My watch list  

UGISense AG is a biotech company dedicated to developing new and innovative antisense therapeutic agents in collaboration with partners from the industry and academia. The developments are made on the basis of a proprietary platform technology, i.e. the UgimeresTM. The company, which was first established in 2016, is being financed by private investors and has been accredited by the Federal Office of Economics and Export Control (BAFA) (within the scope of their Funds for Venture Capital program).

More about UGISense
  • News

    UGISense AG secures new financing

    Following the seed financing round in 2016, UGISense AG has again been able to successfully complete a funding round. In addition to all founding investors (experienced business angels in the field of biotechnology and the Lead Discovery Center Dortmund), SeedCapital II KG from Dortmund as ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE